Comparison of Glyburide and Insulin In Women with Gestational Diabetes Mellitus and Associated Perinatal Outcome: a Randomized Clinical Trial
,
Abstract
Insulin is currently the drug of choice in treating patients with gestational diabetes mellitus but insulin is expensive, inconvenient to store and use and probably associated with more risks of asymptomatic hypoglycemia in comparison with some oral agents. This randomized clinical trial was conducted to evaluate the efficacy and safety of glyburide in patients with gestational diabetes mellitus in comparison with insulin therapy. Pregnant women aged between 18-45 years with singleton pregnancies and in their 24-36 weeks of gestation were assessed for eligibility. Women with gestational diabetes mellitus were randomly allocated to two insulin and glyburide groups and compared with maternal and neonatal outcome. Ninety-six women with gestational diabetes mellitus enrolled in the study. At screen and treated fasting and post-prandial blood glucose levels were similar in both groups. Time for beginning the treatment to control the glycemic index was 28.30 (±20.60) days in the insulin group and 22.56 (±18.86) in the glyburide group. There was no statistically significant difference in time-to-control the blood glucose level in two studied group. Time, between beginning the treatment of GDM and delivery, was 53.22 (±28.96) days in the insulin group and 56.67 (±30.47) in the glyburide group. There was no statistically significant difference between the times of treatment-to-delivery in two studied groups. There were no statistically significant differences between maternal and neonatal outcomes in two studied groups. Glyburide can effectively and safely control the glycemic index in women with gestational diabetes mellitus in comparison with insulin.
Wendland EM, Torloni MR, Falavigna M, et al. Gestational diabetes and pregnancy outcomes:a systematic review of the World Health Organization (WHO) and the International Association of Diabetes in Pregnancy Study Groups (IADPSG) diagnostic criteria. BMC Pregnancy Childbirth 2012;12(1):23.
DeSisto CL, Kim SY, Sharma AJ. Prevalence Estimates of Gestational Diabetes Mellitus in the United States, Pregnancy Risk Assessment Monitoring System (PRAMS), 2007-2010. Prev Chronic Dis 2014;11:E104.
Ferrara A. Increasing Prevalence of Gestational Diabetes Mellitus: A public health perspective. Diabetes Care 2007;30(Suppl 2):S141-6.
Cundy T, Ackermann E, Ryan EA. Gestational diabetes: new criteria may triple the prevalence but effect on outcomes is unclear. BMJ 2014;348:g1567.
Yogev Y, Ben-Haroush A, Chen R, et al. Undiagnosed asymptomatic hypoglycemia: diet, insulin, and glyburide for gestational diabetic pregnancy. Obstet Gynecol 2004;104(1):88-93.
Moore TR. Glyburide for the Treatment of Gestational Diabetes: A critical appraisal. Diabetes Care 2007;30(Suppl 2):S209-3.
Langer OD, Conway DL, Berkus MD, et al. A comparison of glyburide and insulin in women with gestational diabetes. N Engl J Med 2000;343(16):1134-38.
Gabbe SG, Gregory RP, Power ML, et al. Management of diabetes mellitus by obstetrician-gynecologists. Obstet Gynecol 1998;91(5 Pt 1):643-7.
Corbet A, Bucciarelli R, Goldman S, et al. Decreased mortality rate among small premature infants treated at birth with a single dose of synthetic surfactant: a multicenter controlled trial. J Pediatr 1991;118(2):277-84.
Magdy MA, Allam A, Mostafa AA, et al. Oral Hypoglycemic as Attractive Alternative to Insulin for the Management of Diabetes Mellitus during Pregnancy. Gynecol Obstet (Sunnyvale) 2014;4:193.
Elliott BD, Langer O, Schenker S, et al. Insignificant transfer of glyburide occurs across the human placenta. Am J Obstet Gynecol 1991;165(4 Pt 1):807-12.
Garcia Bournissen F, Feig DS, Koren G. Maternal-fetal transport of hypoglycaemic drugs. Clin Pharmacokinet 2003;42(4):303-13.
Anjalakshi C, Balaji V, Balaji S, et al. A prospective study comparing insulin and glibenclamide in gestational diabetes mellitus in asian Indian woman. Diabetes Res Clin Pract 2007;76(3):474-5.
Kremer CJ, Duff P. Glyburide for the treatment of gestational diabetes. Am J Obstet Gynecol 2004;190(5):1438-9.
Chmait R, Dinise T, Moore T. Prospective observational study to establish predictors of the glyburide success in women with gestational diabetes mellitus. J Perinatol 2000;24(10):617-22.
Jacobson GF, Ramos GA, Ching JY, et al. Comparison of glyburide and insulin for the management of gestational diabetes in a large managed care organization. Am J Obstet Gynecol 2005;193(1):118-24
Kimber-Trojnar Z, Marciniak B, Leszczynska-Gorzelak B, et al. Glyburide for the treatment of gestational diabetes mellitus. Pharmacol Rep 2008;60(3):308-18.
Conway DL, Gonzales O, Skiver D. Use of glyburide for the treatment of gestational diabetes: the San Antonio experience. J Matern Fetal Neonat Med 2004;15(1):51-5.
Fines V, Moore T, Castle S. A Comparison of Glyburide and Insulin Treatment in Gestational Diabetes Mellitus on Infant Birth Weight and Adiposity. 189(6):S108.
Holt RI, Goddard JR, Clarke P, et al. Apost natal fasting plasma glucose in useful in determining which women with gestational diabetes should undergo a postnatal oral glucose tolerance. Diabet Med 2003;20(7):594-8.
Moretti ME, Rezvani M, Koren G. Safety of glyburide for gestational diabetes: a meta-analysis of pregnancy outcomes. Ann Pharmacother 2008;42(4):483-90.
| Files | ||
| Issue | Vol 53, No 2 (2015) | |
| Section | Original Article(s) | |
| Keywords | ||
| Glyburide Insulin Gestational Diabetes Mellitus Treatment | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
